32233-38-8

Upstream product

• 62447-84-1 (3aR,4S,5S,6R,6aR)-4-Benzyloxymethyl-6-iodo-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 
• 31767-37-0 6-Benzyloxymethyl-7-hydroxy-8-iodo-2-oxabicyclo<3.3.0>octan-3-one 
• 110-87-2 3,4-dihydro-2H-pyran 

Downstream Products

• 65025-95-8 (3aR,4S,5R,6aS)-4-({[dimethyl(2-methyl-2-propanyl)silyl]oxy}methyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one 
• 74028-42-5 3α-hydroxy-7-oxo-2β-benzyloxymethylbicyclo<3.3.0>octane tetrahydropyranyl ether (β-isomer) 
• 73996-31-3 3α-hydroxy-7-oxo-2β-benzyloxymethylbicyclo<3.3.0>octane tetrahydropyranyl ether (α-isomer) 
• 69552-55-2 (5E)-6a-carbaprostaglandin I₂ methyl ester 
• 71884-06-5 (5E,16R)-6α-carbaprostaglandin I₂ methyl ester 
• 105198-56-9 4-[(1R,2S,3R)-2-Benzyloxymethyl-5-oxo-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-3-oxo-N-phenyl-2-(triphenyl-λ⁵-phosphanylidene)-butyramide 
• 88294-73-9 (5R,6S,6aR)-6-Benzyloxymethyl-5-(tetrahydro-pyran-2-yloxy)-4,5,6,6a-tetrahydro-1H-pentalen-2-one 
• 69552-46-1 (5E)-carba-PGI2 
• 82259-28-7 [(4S,5R)-4-Benzyloxymethyl-2-oxo-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-6a-yl]-trimethylsilanyl-acetic acid methyl ester 
• 73995-84-3 methyl 3α-hydroxy-2β-(benzyloxymethyl)-5ξ-(carbomethoxymethyl)cyclopentane-1ξ-acetate tetrahydropyran-2-yl ether 
• 74028-40-3 [(1R,2S,3R)-2-Benzyloxymethyl-5-hydroxy-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-acetic acid methyl ester 
• 69609-77-4 carbacyclin 
• 82293-07-0 3α-hydroxy-7-oxo-2β-benzyloxymethylbicyclo<3.3.0>octane (β-isomer) 
• 74080-58-3 methyl 3α-hydroxy-2β-(benzyloxymethyl)-5-(carbomethoxymethylene)cyclopentane-1α-acetate 3-tetrahydropyran-2-yl ether 

Relevant academic research and scientific papers

Synthesis of corey lactone via highly stereoselective asymmetric diels-alder reaction

We have succeeded in a highly stereoselective asymmetric Diels-Alder reaction between a chiral acrylate 3a derived from commercially available D-pantolactone 2 and 5-benzyloxymethyl-cyclopentadiene 4 to give the adduct 5a in 94% d.e. and 79% yield for the synthesis of Corey lactone 1.

Novel prostacyclin derivatives and a process for the preparation thereof

Compounds of the formula STR1 wherein R1 is (a) hydrogen, (b) C1-10 alkyl, (c) C1-10 alkyl substituted by halogen; C1-4 alkoxy; C6-10 aryl; C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group; di-C1-4 -alkylamino; or tri-C1-4 -alkylammonium, (d) C4-10 cycloalkyl, (e) C4-10 cycloalkyl substituted by C1-4 alkyl, (f) C6-10 aryl, (g) C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S; A is --CH2 --CH2 --, trans--CH=CH-- or --C C--; W is hydroxymethylene, RO-methylene, CH3 or CH3, STR2 wherein OH or OR is in the α- or β-position and R is an in vivo hydrolyzable and physiologically acceptable ether or acyl group which is conventional for modifying OH groups in prostaglandins; D and E together are a direct bond, or D is C1-10 alkylene, C1-10 alkenylene or C1-10 alkynylene or one of these groups substituted by fluorine, and E is oxygen, --C C-- or a direct bond; R2 is (a) a C1-10 hydrocarbon aliphatic radical, (b) a C6-10 hydrocarbon aliphatic radical substituted by C6-10 aryl or by C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group; (c) C4-10 cycloalkyl, (d) C4-10 cycloalkyl substituted by C1-4 alkyl, (e) C6-10 aryl, (f) C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group; or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S; and R3 is OH or OR; and, when R1 is hydrogen, the salts thereof with physiologically compatible bases, are effective as antihypertensive, bronchiodilators, thrombocyte aggregation inhibitors, inter alia.